Recombinant Adeno-Associated Viruses for use in Gene Therapy

Web Published:

Princeton University Invention # 90-0954


The technology as described in US patent # 5,753,500 relates to a method for producing substantially pure stocks of recombinant adeno-associated virus, free of the adeno-associated helper virus found associated with previously available recombinant AAV. These pure stocks can be used to introduce exogenous genetic sequences into cells, cell lines, or organisms. In the absence of the adeno-associated helper virus, the recombinant AAV will remain stably integrated into cellular DNA. Novel  recombinant AAV vectors and adeno-associated helper viruses are also described which may provide for the increased expression of the gene product of interest.


Princeton is currently seeking commercial partners for the further development and commercialization of this opportunity. Patent protection is pending.




Samulski RD, Chang LS, Shenk T, Helper Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression, Journal of Virology, Sept 1989, p. 3822-3828.


For more information on Princeton University invention # 90-0954 please contact:


                        Laurie Tzodikov

                        Office of Technology Licensing and Intellectual Property

                        Princeton University

                        4 New South Building

                        Princeton, NJ 08544-0036

                        (609) 258-7256

                        (609) 258-1159 fax



Patent Information:
For Information, Contact:
Ms. Jean Mahoney
Director of Technology & Trademark Lic.
Princeton University
Mark Labow
Stephan Baim
Arnold Levine
Thomas Shenk